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ABSTRACT 
 
Finding the complex semantic relations between existing drugs and new diseases 
will help in the drug development in a new way. Most of the drugs which have found new 
uses have been discovered due to serendipity. Hence, the prediction of the uses of drugs for 
more than one disease should be done in a systematic way by studying the semantic 
relations between the drugs and diseases and also the other entities involved in the 
relations. Hence, in order to study the complex semantic relations between drugs and 
diseases an application was developed that integrates the heterogeneous data in different 
formats from different public databases which are available online. A high level ontology 
was also developed to integrate the data and only the fields required for the current study 
were used. The data was collected from different data sources such as DrugBank, 
UniProt/SwissProt, GeneCards and OMIM. Most of these data sources are the standard 
data sources and have been used by National Committee of Biotechnology Information of 
Nation Institute of Health. The data was parsed and integrated and complex semantic 
relations were discovered. This is a simple and novel effort which may find uses in 
development of new drug targets and polypharmacology.   
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CHAPTER 1. INTRODUCTION 
Drug discovery is a process of discovering and designing drugs and is generally 
related to the fields of medicine, pharmacology and biotechnology. Despite advances in 
technology and understanding of biological systems, drug discovery is still a lengthy 
(taking about 15 years of time from proposal to being used as treatment for patients [1]), 
expensive (costing about $800 million to $1 billion [1]), difficult, and inefficient process 
with low rate of new therapeutic discovery [1]. Development of a new drug from scratch is 
a complex process that involves extensive research of the proposed compounds. Between 
5000 to 10,000 compounds that are proposed for a potential drug, only about 2.5% to 5% 
of the compounds get approved for preclinical trial. Out of these only 2% may get 
approved for clinical trial, further only 1 compound becomes an approved drug [1 - 4].  
Drug repositioning is an effective solution to the aforementioned problem [5]. It is 
the application of the existing drugs to new indications or new diseases. An existing drug 
has passed significant pre-clinical and clinical tests. Its toxicity and other effects are 
already known. Hence the cost of using it for some other disease will be much less 
compared to developing a drug from scratch. Drug repositioning is the study of interaction 
of drugs with multiple targets. Conventional drug design follows the principle of “one 
gene, one disease, one drug” i.e. one drug is targeted for the treatment of one disease 
caused by one gene. However, the same drug can be used with multiple diseases. Most of 
the repositioned drugs that are being currently used have been developed by chance on 
observation of the side-effects of the drug [6,7]. A compound or a drug may be related to 
new diseases. For example the side effect of one drug may be the treatment of another 
disease. However, this relationship might not have been identified earlier and the 
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information relating the drug and the new application might not be available in detail. 
Hence, a detailed study involving the proteins, genes, pathway and other important factors 
should be carried out to study the polypharmacological action of drugs rather than 
discovering the effects by mere observation.  
To solve the aforementioned problems, the main aim was to discover valuable 
relationships between drugs, proteins, genes, and diseases for this study. The present work 
involves the integration of data over various diverse domains such as chemical, biological 
etc. The data that has to be integrated over these domains may also be disparate data in 
multidimensional and heterogeneous forms. To reconcile the heterogeneity problem, 
Semantic Web and knowledge representation techniques have been adopted for effective 
integration of data as well as find the appropriate associations between the drugs and 
diseases and therefore find the most effective drug against a disease by providing 
appropriate ranking of the drugs. 
In the proposed approach, Semantic Web techniques are used to represent the data 
sources used in the study. Semantic Web is the extension of the current World Wide Web 
which contains a large amount of linked information over various platforms. Combining 
and linking such disparate data is a challenge today which can be assisted with Semantic 
Web technologies.  The focus in this work, in particular, is on Semantic Associations. 
Semantic Associations are complex relationships between entities, events and concepts. 
With the help of these associations the information contained can be understood and 
interpreted differently. They may even provide information that may not be easily 
determined otherwise.  
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An entity may be related to another entity directly or through one or more 
intermediate entities. An association where an entity is related to another entity through 
intermediate entities is extremely important in various applications. In the human body a 
number of processes take place. The chemicals in the body may be broken down to make 
simpler chemicals or form other chemicals used in the functioning of the body. This 
involves various genes, proteins, enzymes etc. When one molecule is transformed into 
another molecule through a series of steps, the process is called as pathway. The pathway is 
catalyzed by enzymes at various steps. Diseases affect the body physically and may affect 
the internal processes of the body and various pathways. In order to cure the diseases, 
drugs are used which are foreign molecules. These foreign molecules are converted into 
other molecules and help in curing the disease. This might involve inhibiting the pathway 
of various organisms including bacteria causing the disease. Thus the drugs may be related 
to diseases either through the protein targets or through the genes and pathways. The 
information about the various molecules in the body and their properties and functions as 
well as the processes that interact with these molecules is widely available in the public 
databases such as DrugBank [8], KEGG [9-11], OMIM [12]. The drugs can be related to 
the diseases via intermediate protein targets. The protein targets are directly related to the 
diseases through OMIM database [10]. The drugs and the diseases may also be related  via 
genes and pathway they inhibit.  
An entity may be related to another entity in one or more than one way. The entity 
e1 and e5 could be related through different entities such as e2, e3 or e4. The different 
paths that may exist between e1 and e5 could be e1 – e2 – e5, e1 – e3 – e5 or e1 – e4 – e5 
(Figure 1.1). For example a student is related to Professor by the relationship “teaches” but 
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may also be related through other ways as both student and Professor may be residing in 
the same geographical location or they may be the member of same organization, or they 
may even have same hobbies and interests. A drug can be linked to a disease by more than 
one protein target as well as more than one side effects that it may have on the human 
being. 
 
 
 
 
 
 
Figure 1.1. Relation between Two Entities through Different Paths 
Thus there may be hundreds of such associations between two entities. However, 
many of these paths may not provide meaningful information to the user and may be 
considered as irrelevant as the user may not consider the context in which those paths could 
be useful. Hence, in order to find the relevant paths or Semantic Associations, the user’s 
domain or region of interest or the context in which the associations would be interpreted 
should be determined. 
A Semantic Association is a sequence of complex relationship between the entities 
which may be from disparate sources.  They have a directed path from one entity to 
another. Also, more than one path may exist between the entities or they may be associated 
in more than one way.  Hence, a search algorithm is needed to return one or more paths 
result. In order to do that the search algorithm needed to be constrained (bounded) so that 
e1 
e2 
e3 
e5 
e4 
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the results are meaningful.  In the approach presented here, the associations between the 
drugs and diseases were considered. These associations were found by integrating the data 
of drugs, proteins, targets, genes and diseases across several websites. Once the 
associations were found, they were examined for the number of ways in which one entity is 
associated with another. As stated earlier, the search can result into a number of paths 
which may not be useful to the user as they may not be in context in which the user is 
querying. Hence, these paths need to be relevant and the relevance could be found by 
ranking the paths in between the Semantic Associations.  
The association between two entities within the domain of interest or context can be 
ranked based on their relevance. An association is ranked the highest when it provides the 
maximum information in a given context. Hence, the context should be defined within 
which the associations need to be ranked. The context also includes the associated 
properties and the classes.  Besides this the length of the association is also considered 
important to provide the relevant information 
It has been observed that there is no single method for ranking the Semantic 
relationships between the entities, as a number of factors have to be considered. Hence, an 
approach had to be considered that had an edge over the other algorithms reported. Also the 
method should be flexible enough to consider the different factors involved such as length 
of the association, context in which it is to be determined, as well as the frequency of their 
occurrence.   
Hence in the present work, the iterative deepening algorithm has been used to 
search for the paths in Semantic Associations between the drugs and the diseases. The 
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associations between the drugs and the diseases are identified using intermediary genes, 
proteins and targets. The algorithm also considers many factors that may be involved 
during the ranking approach. As stated earlier, the drug development is a lengthy and 
expensive process that may not give very promising results. Hence, the new uses for 
existing drugs would be more useful than developing a drug from scratch. Rather than 
finding the new uses by chance, studies could be carried out for finding other uses. In this 
work, an attempt of a systematic study between the drugs and their effects on the diseases 
and the side effects that may lead to the new use of existing drugs was made.  
In summary, the contribution of this paper can be summarized as: 
1. A novel scheme is proposed to discover drugs by mining data from dispersed drug-
related knowledgebases. 
2. The present application helps in finding the Semantic Associations between the 
drugs and the diseases from the ontology prepared using disparate data from 
different websites.  
The following of the paper is organized as follows. Chapter 2 provides an overview 
of some background knowledge and related work, Chapter 3 gives the System Design as to 
how the studies on finding the appropriate paths or Semantic Associations between the 
drug and the disease can be found out. It also gives results and discussion and Chapter 4 
provides the conclusions and future work. The References used in the paper are listed in the 
end. 
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CHAPTER 2. RELATED WORK AND BACKGROUND KNOWLEDGE 
2.1 Semantic Web  
Semantic Web can be considered as the largest repository of information on the 
web. The information contained on the Semantic Web has the user terminology, vocabulary 
and the language from across the globe. It provides the capability of storing multiple names 
of the same product or aliases, with the help of which the users of Semantic Web can 
search using different name, spellings of that name, code names, or acronyms for the same 
product as well as producing the same result upon querying by linking and integrating the 
disparate data[13]. Semantic Web can interpret web pages consisting of knowledge and 
data that can be processed by computers making it much more understandable without the 
human intervention 
The Semantic Web defines data on the Internet in a meaningful and functional way 
that is specifically understandable by computers. Internet information retrieval systems 
(search engines) will soon be able to more efficiently query and retrieve relevant 
information from documents by extracting semantic metadata from document headers. 
However, semantic data is able to reveal much more complex relationships than simple 
information retrieval is able. By querying semantic relationships artificially intelligent 
agents are able to discover complex relationships by searching for paths via chaining 
semantic triples.  
As more and more web bases store semantic metadata on their pages, the number of 
relationships between entities on the Internet, and descriptions of data will need to be 
further defined. Basic ontological structures are being developed to constrain that 
information, but only in schema form. Instances of semantic structures still reside in 
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text/xml format on the pages, and in order to be searched efficiently they must be managed 
in a more structured system. In addition, as the number semantic relationships explodes on 
the Internet, efficient search and ranking algorithms will need to be created in order to 
digest the data and discover complex semantic relationships- i.e. relationships between web 
entities that span across several semantic hops.  
The Semantic Web itself is a globally linked mesh of ontological information to be 
understood by machines. This, in turn, is a subset of the World Wide Web which is a 
globally linked mesh of information understood by humans. The Semantic Web makes use 
of ontological schemas to define data in web documents and creates instances of those 
objects defined in the schemas as metadata added to web documents. This metadata can 
then be searched by artificially intelligent agents to produce meaningful search results or 
provide more detailed about web resources.  
2.2 RDF (Resource Description Framework)  
Generally, XML RDF is the format used for the semantic metadata added to web 
pages- and is quickly becoming a W3C standard for this purpose. RDF provides an 
ontological description of a resource and is in the basic format of a generic ontological 
triple (discussed in the next section).  Representing the triples efficiently, is not as easy as it 
sounds, different types of formats have been developed, for external and internal 
processing purposes. One of these external RDF formats is known as Notation3, a plain 
text format devised by Tim Berners-Lee (who proposed World Wide Web and Semantic 
Web), which is easy to learn, and easy to process [14].   
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2.3 Generic Ontological Triples 
A triple is a semantic statement that describes a relationship, and is usually defined 
using RDF and RDF Schemas [14]. They define properties of the resource they describe or 
create relationships between different resources. Their basic purpose is to make natural 
language data “understandable” to machines, so that relationships or objects can be 
processed for various purposes instead of just parsed. Triples are built on two ontological 
structures: entities and predicates, where entities are the subject and object of a predicate- 
which is a relationship between the two entities [15]. They usually take the form: <Subject, 
Predicate, Object>. This triple can be read: “The subject entity is related to the object entity 
by the predicate”, or alternatively “The subject predicates the object”.  
Usually the two entities in a triple have URIs (Uniform Resource Identifiers), in 
order to maintain the universality of those objects. Using URIs allows us to know the exact 
resource of the statement and the property to be assigned to it. Triples may consist of three 
URIs, one for both entities and the predicate have the strongest description. The second 
generation of the Semantic Web will focus on adding semantic annotations that software 
can understand and from which humans can also benefit because of its natural readability – 
but it will always necessarily be in triple form.  
2.4 Semantic Relations  
The main goal of this paper is to discover complex semantic relationships between 
entities defined by ontologies. A complex semantic relation can be defined as the path 
between two entities where a path is defined as: 
e1, P1, e2, P2, … , en-1, Pn-1, en 
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where ei is an entity and Pj is a predicate or property that defines a relationship between 
two entities, ei and ei +1. Therefore this denotes a complex semantic relation between entities 
e1 and en.  Essentially this is the chaining of ontological triples, where the next triple has 
subject that was the object of the previous triple:  
<Subject1, Predicate1, Object1> <Object1, Predicate2, Object2>…<Objectn-1,Predicaten, 
Objectn> 
Semantic associations are meaningful complex relationships between entities, 
events and concepts. They provide meaningful information so that it is understandable and 
new relationships could be discovered over the Semantic Web [16]. Various studies have 
been carried out over the years to find the complex relationships between the entities using 
Semantic Web. Complex semantic relationships between the entities have a directed path 
or a sequence to get from one entity to another [17]. RDF is a standard for describing and 
exchanging the information of the web resources. Although querying is not well supported 
in RDF, ρ-queries help in querying for Semantic Associations on the Semantic Web and 
find some relationships [17].  
An important measurement for these complex relations is the number of hops it 
takes to reach en from e1. Hop count is the number of traversals down a directed acyclical 
graph tree created by these relationships. Alternatively, the number of hops is the number 
of triples required to generate the path. Hops are also a measure of depth for these 
relationships.  
Because of the extremely large metabase being queried, there may be too many 
results many of which may not be of importance. Therefore ranking of complex 
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relationships discovered is also of vital importance. There is a need for a flexible ranking 
approach that would allow the identification of the most interesting and meaningful 
Semantic Associations between two entities which is effective and efficient in terms of 
time, space and relationship complexity. Unfortunately there is no natural heuristic for 
determining this since there is no cost other than hops associated with these relations.  
2.5 Ranking Semantic Associations 
Searching and ranking of documents can be done within some relevance measures 
such as relevance weights that are assigned to the relationships by the humans and a 
relevance threshold. The relationships of named entities can be analyzed with respect to a 
query.  The results can be obtained within this threshold [18-20]. 
The research in life sciences had produced huge amount of data. Large amount of 
this data is available as public databases for further research and studies. They contain 
information from research areas including genomics, proteomics, metabolomics, 
microarray gene expression, and phylogenetics. [21]. Open life science and biomedical 
Ontologies are present on the World Wide Web. Since these ontologies are from varied 
sources they can be associated using RDF as triples. Hence, molecular biology could be 
related to bioinformatics which in turn could be related to drug delivery by relating specific 
gene to a specific protein which could be a target protein or a specific drug. The genes and 
the proteins could be related using the SwissProtID. The associations between drugs and 
the metabolic pathways could also be studied using the Semantic Web. The genes are 
associated with the metabolic pathways using the PathwayID [22]. Thus, gene data from a 
genomic database and corresponding protein data from a protein database can be merged 
together within RDF documents giving meaningful associations.  
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Also, since many association paths can exist between any two given entities, these 
paths are needed to be ranked to find the most relevant path within the system biology 
space. The entities can be associated with each other based on the context in which they are 
being considered. The genes can be easily associated with the proteins in the similar way If 
the proteins are localized in a particular tissue (context) then those proteins could be linked 
to the corresponding genes by the functional analysis of the genes. 
Semantic Web ranks different types of entities on the web. This includes the 
documents, relationships, queries, ontologies etc. Different approaches have been 
employed to determine the ranking of each of these.  Ranking of the semantic relationships 
is different than ranking of documents. In Semantic Web ranking the queries are ranked by 
finding the relevance in the keywords returned as the result of the query. The results of the 
query should be the association between entities which is the path between them.  A very 
popular algorithm, PageRank Algorithm is a link analysis algorithm which is commonly 
employed to find the ranking of the documents hyperlinked to each other by assigning the 
weights to the incoming as well as outgoing links. It uses a wide data with 500 million 
variables and 2 billion terms [23].  The ObjectRank system applies authority-based ranking 
to keyword search in databases modeled as labeled graphs [24]. The nodes contain the 
keywords and are connected semantically to the other nodes by authority. Each node is 
ranked according to its authority with respect to the particular keywords. Weights are 
assigned to global importance, each keyword of the query as well as the importance of a 
result actually containing the keywords. The results that actually contain the keywords are 
ranked higher than being referenced by nodes containing them.. Teoma is a search engine 
which is used or ranking the search results on the web. It analyzes the web pages and 
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groups them based on their subject [25]. This algorithm also uses the popularity technique 
to rank the results. ReConRank [26] is a graph based ranking algorithm. The ranking is 
applied in the depth to graphs and subgraphs. It combines two approaches. It ranks the 
RDF graphs by ranking the data graph as well as the data provenance graphs. SemRank 
[27] is an algorithm based on relevance and ranks the results based on the usefulness of the 
result to the user. It has the heuristics to order the search results based on the user need.  
HITS is a link analysis algorithm that rates Web pages [28]. The scheme assigns two scores 
for each page: its authority, which estimates the value of the content of the page, and its 
hub value, which estimates the value of its links to other pages.  Topic-sensitive PageRank 
[29] is an extension of PageRank algorithm where a set of PageRank vectors are computed 
as opposed to only one to produce more accurate results. These vectors are related to the 
topics or the subject of the query rather than the web pages. They rank the web pages based 
on the relevance of the topic of the query contained in those web pages [29].  PopRank is a 
domain-independent object-level link analysis model to rank the objects within a specific 
domain [30]. A popularity propagation factor is assigned to each type of object relationship 
effect of popularity propagation factors for these heterogeneous relationships over the 
popularity ranking. The two page ranking algorithms commonly used in Web structure 
mining are HITS and PageRank. In both algorithms all links from one node to another are 
considered equal when distributing rank scores. The weighted PageRank algorithm (WPR) 
is an extension to the standard PageRank algorithm.  It considers both incoming links as 
well as the outgoing links of the pages. Both types of links are given equal importance 
while ranking. The rank scores are based on the popularity of the pages. WPR performs 
better than the conventional PageRank algorithm in terms of returning a larger number of 
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relevant pages to a given query [31]. A Semantic Web portal, called OntoKhoj [32] is 
designed to simplify the Ontology Engineering process. The methodology in developing 
OntoKhoj is based on algorithms used for searching, aggregating, ranking and classifying 
ontologies in Semantic Web. The proposed OntoKhoj would 1) allow agents and ontology 
engineers to retrieve trustworthy, authoritative knowledge, and 2) expedite the process of 
ontology engineering through extensive reuse of ontologies.  
2.6 Bio2RDF: Linked Data for the Life Sciences  
The Bio2RDF project is a network of the life science data which is coherently 
linked. Different databases across life sciences platform have been linked using open-
source Semantic Web technologies to provide support biological knowledge discovery. It 
consists of different tools so that it can integrate the data from different databases which 
can then be queried using SPARQL which is an RDF Query Language [33]. It uses both 
syntactic and semantic data integration techniques, and presents the data on a distributed 
network server. It consists of 2 billion triples and is a publicly available system [34]. 
2.7 Linked Open Drug Data  
In order to develop new drugs to cure diseases a large amount of biomedical data 
from various heterogeneous sources has to be integrated to get the relevant information 
about the disease to be treated. The new drugs to be developed are expected to be more 
effective against the disease than the existing drug and having less side effects.  Linking 
Open Drug Data (LODD) project helps to bring the data sources together onto the Web of 
Linked Data and facilitates the integration of data. All the data and the datasets used from 
different sources have been strongly linked and also linked to the other Linked data. LODD 
contains 8.4 million RDF triples and the data from the data sources about drugs, Chinese 
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medicine, clinical trials, diseases and pharmaceutical companies have been linked together 
[35].  
2.8 Drug Delivery and Polypharmacology 
Drug discovery is a process of discovering and designing of drugs and is generally 
related to the fields of medicine, pharmacology and biotechnology. Drug discovery is a 
lengthy process and may take upto 15 years from initial stages of discovery to the time it is 
available for treating patients. The cost involved to develop a drug from scratch is as high 
as $800 million to $1 billion.  Hence to develop an effective drug, it is necessary to 
understand how disease and infection are controlled at the molecular and physiological 
level. In order to do that the disease to be treated should be understood as well as possible, 
the underlying cause of the disease should also be found out. To understand the disease 
completely it is essential to understand as to which genes are affected by the disease as 
these genes in turn affect the proteins that they encode. Also since the proteins interact with 
each other in living cells, they affect the tissue in the areas in which the cells are located 
and as a result affect the patient on the whole. On gaining the complete understanding of 
the disease a target protein or gene is identified which is involved in the disease. Once the 
candidate for the new drug to be developed is identified, it is characterized and screened 
using high throughput screening etc. for the efficiency as a potential drug. Despite 
advances in technology and understanding of biological systems, drug discovery is still a 
lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic 
discovery. Currently, the research and development cost of each new molecular entity 
(NME) is approximately US$1.8 billion. After considerable research, out of 5000 – 10000 
compounds that are proposed for a potential drug for a disease only about 250 get approved 
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for preclinical trial, where they are tested in vivo as well as in vitro. This process takes 
about 3 - 6 years. Further out of the 250 compounds approved for pre-clinical trial only 5 
get approved for the clinical trial which takes about 6 – 7 years and from that only one gets 
approved as a drug to cure the disease [1-4]. Figure 2.1 shows a typical drug discovery 
process. While designing a drug, natural products play a very significant role. The drugs 
could be plant derived, such as Belladonna, from the microbes such as streptomyces or 
marine invertebrates. Most drugs are derived from the natural products. However, despite 
the advances in the chemical synthesis techniques as well as combinatorial and 
cheminformatics, there has not been no increase in the number of drugs that are developed. 
 
Figure 2.1. The Process of Drug Development [36] 
2.9 Polypharmacology or Drug Repositioning 
Polypharmacology is the study of interaction of drugs with multiple targets [37, 38]. 
Conventional drug design follows the principle of “one gene, one disease, one drug”. 
However, the same drug can be used with multiple diseases. Since the process of drug 
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discovery takes a long time of approximately 15 years and for every 5000-10000 proposed 
compounds, only one gets approved as a drug for the treatment of diseases and use on 
humans, the chances are that if a drug has been selected for a single target, it might be 
unsuccessful as it might be low in clinical efficacy. A drug can have a polypharmacological 
action on the targets that may fall in the same pathway. If the drug is able to interrupt the 
pathway at multiple points then it exhibits high efficacy. Also the already approved drugs 
may be less selective and may affect more than one protein target thereby affecting more 
than one disease. The examples of this drug repositioning are the cancer drug such as 
Gleevac (imatinib) [39] can bind to multiple kinases. Other examples are Propiomazine 
(Largon) and Promazine (Sparine) which have 14 targets each [40]. Also there might be 
certain diseases where a single gene or single protein may not be responsible for it. Hence, 
one drug may be insufficient to treat the disease. Thus the drug-target pair could be crucial 
for polypharmacology. There could be many-to-many relationships between the target – 
drug pairs. With the help of Semantic Web, the paths between the drug and the target can 
be found out and with the help of a suitable ranking technique, the most suitable drug for a 
target can be determined.  
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CHAPTER 3. SYSTEM DESIGN 
3.1 Overview 
Large amount of data is available on the Internet and this data is ever growing. With 
the advancements in technology, there have been numerous data sources which are publicly 
available on the Internet. The biological and chemical fields have been of particular interest 
as they provide information about the humans. Numerous data sources are available for 
genes, proteins, genetic information, drugs, diseases etc. The study of the complex 
biological systems and the effect of drugs on these systems is possible by use of intelligent 
systems like Semantic Web. With the help of Semantic Web the available data can be 
integrated and meaningful results can be obtained [41,42]. The use of Semantic Web in life 
sciences, healthcare and drug discovery has already been demonstrated [43-45]. 
To study the relationships between the drugs and diseases and possibly to find the 
polypharmacological properties of drugs the data was taken directly from the websites and 
integrated to get the required data for the current study. The websites from where the data 
was taken are all open data sources. Many data sources are available on the Internet that 
contain similar and overlapping data about a particular entity. Hence, only one data source 
was chosen for each entity for the current study.   
The Semantic Web has the advantage of integrating the relevant data from multiple, 
varied resources and possibly incompatible formats. The web resources are defined by 
Resource Description Framework (RDF) in the form of triples as <Subject, Predicate, 
Object>. The semantic associations are found by chaining of these triples. These 
associations are defined by ontologies. A complex semantic relation can be defined as the 
path between two entities where a path is defined as: 
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e1, P1, e2, P2, … , en-1, Pn-1, en 
where ei is an entity and Pj is a predicate or property that defines a relationship between 
two entities, ei and ei +1. Therefore this denotes a complex semantic relation between entities 
e1 and en.  Essentially this is the chaining of ontological triples, where the next triple has 
subject that was the object of the previous triple:  
<Subject1, Predicate1, Object1> <Object1, Predicate2, Object2>…<Objectn-1,Predicaten, 
Objectn> 
For Complex Relation discovery a search algorithm was the most important 
requirement which was robust and efficient as well as complete and optimal. The path 
result that is found by the search algorithm should be returned as a data type that was 
understandable by the program. The search algorithm should also be able to return multiple 
paths for comparison and ranking purposes. Finally the search algorithm needed to be 
constrained or bounded so that the results are meaningful. The Algorithm used in the 
present study used an Iterative Deepening Depth First Search to minimize space and time 
complexity and to provide complete and optimal complex paths. Complex relations are 
usually multi-hop relations, with goals probably being found at very low levels in the tree- 
therefore IDS returns deeper paths much faster- providing for more meaningful results. 
Many association paths can exist between any two given entities. These paths are 
needed to be ranked to find the most relevant path within the system biology space. The 
entities can be associated with each other based on the context in which they are being 
considered. Semantic Web ranks different types of entities on the web. Different 
approaches have been employed to determine the ranking of each of these.  Ranking of the 
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semantic relationships is different than ranking of documents. In Semantic Web the queries 
are ranked by finding the relevance in the keywords returned as the result of the query. The 
results of the query should be the association between entities which is the path between 
them.  A number of different ranking algorithms have been reported in literature. PageRank 
[23] which analyses the incoming and outgoing links of documents, ObjectRank [24] an 
authority-based algorithm and ReConRank [26] a graph based ranking algorithm etc are 
few examples of ranking algorithms. In the present work, I propose to use the Iterative 
Deepening Depth First search Algorithm which runs repeatedly until it reaches the depth d 
where it finds the shallowest goal. 
3.2 Data Sources 
Numerous data sources are publicly available on the Internet for genes, genetic 
information, pathways, proteins, drugs and diseases. The information contained on many 
data sources may be similar and overlapping for the same entity. Besides this, the data may 
be present in various diverse formats such as text files, XML, different types of database 
formats etc. Integrating such systems could be a challenge which could be overcome with 
the help of Semantic Web. Integrating different systems could produce a network of linked 
drugs, proteins, genes and diseases. It should be possible to query such integrated systems 
to provide meaningful data. Efforts have been made in the past to integrate the biological 
and chemical data using Semantic Web. Some examples include LODD [46], 
YeastHub[47], LinkHub[48], BioDash[49] etc. For the current work the data on drugs was 
used from drugbank[50]. It is the most widely used database on drugs. It has the links to 
other databases such as UniProt[51], GeneCards[52] and OMIM[53] which were also 
considered for study.  
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 Protein data was obtained from UniProt[51] which is a widely used database for 
proteins and protein sequences. It has been used by National Center of Biotechnology 
Information (NCBI) of National Institute of Health (NIH). The proteins which acted upon 
by the drugs in drugbank are identified by the UniProt ID which links them to the protein 
database. Gene data was obtained from GeneCards[52] which contains information about 
all known and predicted human genes and information on diseases was linked in OMIM 
database[53]. 
3.2.1 Integration of Data Sources 
It is very important to define the relationships between the entities accurately as 
well as comprehensively. This is because the entities are taken from the sources where their 
relationships may be very poorly and loosely defined. The ontology was developed by 
integrating the data available online from DrugBank, UniProt, GeneCards and the OMIM 
websites. This was done in order to establish the connectivity or the relationship between 
the drugs, diseases, protein targets and the genes.  Also called as Ontology mapping, 
integration of data sources is an important requirement of this work as the data has been 
used from different websites.  
3.3 Methods of Complex Relation Discovery 
3.3.1 Algorithm 
A number of search algorithms have been reported in literature. The present work 
uses the Iterative Deepening Depth First Search Algorithm. It searches iteratively 
increasing the depth every time until the goal is reached. It is a state space search. It has the 
advantage of both the Breadth First Search as well as the Depth first search as it combines 
the state space efficiency of Depth First Search and completeness of the Breadth First 
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Search. The space complexity of IDDS is O(bd) where b is the branching factor and d is the 
depth of the shallowest goal. The time complexity of IDDS is the same as Depth First 
Search O(bd). In this type of search, the nodes on the lowest level are expanded once, those 
on the next to lowest level are expanded twice, and so on, up to the highest level or root of 
the search tree, which is expanded d + 1 times[54]. So the total number of expansions in an 
iterative deepening depth first search is given as 
(d+1)b0  + (d)b1   + (d-1)b2 + … 2bd-1+ 1bd 
This algorithm was used to minimize space and time complexity for a finite graph 
and to provide complete and optimal complex paths. Complex relations can be represented 
as a graph with a start node and a goal node. The Iterative Deepening Depth First Search 
algorithm can be implemented as follows 
IDDFS(start, goal) 
{ 
  depth = 0 
  while(!true) 
  { 
     result = search(start, goal, depth) 
    depth = depth + 1 
  } 
  return result 
} 
 
search(start, goal, depth, visited)  
{ 
  if ( depth >= 0 )  
   { 
    if (start == goal ) 
      return start 
 
 visited.insert(start) 
 
 
    for each child in expand(node) 
     if(!visited) 
      search(child, goal, depth-1, visited) 
 
  }} 
Algorithm 1. Iterative Deepening Algorithm for Relation Discovery [55] 
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Different methods can be used to find a complex relation between two entities. An 
important measure for these complex relations is the number of hops it takes to reach en 
from e1. For the current work the number of hops is limited to 4,  
3.4 Problem Statement 
 Drug development has been a challenging field for a long time. It presents the 
problem of high cost, long development time and low success rate. With the advancements 
in technology, numerous data sources are available for genes, proteins, genetic information, 
drugs, diseases etc. These can be used to study the polypharmacological properties of the 
drugs to reduce the cost of drug development. The available data is disparate in nature. 
Integrating the heterogeneous data to find meaningful results has always been a challenge. 
To achieve this, heterogeneous data across different knowledge domains needs to be linked 
in such as way as to effectively find the associations of the drugs to potential new uses. 
3.5 Contribution to the Paper  
In this work an attempt is made to integrate the heterogeneous data over two 
different domains – chemical and biological to find the relationship between the drugs and 
diseases. The use of Semantic Web to integrate the heterogeneous data over these domains 
is demonstrated. For this purpose the search algorithm was implemented using a simple 
programming language and the associations between the drugs and diseases can be 
retrieved using SQL rather than complex methods. 
 24 
 
3.6 Experimental 
3.6.1 Omim Model 
This section discusses the implementation of software to discover complex 
semantic relations: The main role of Omim is to find complex relationships between two 
input entities namely a drug and a disease.         
3.6.2 Software Requirements 
Python 2.7.2: The system developed in this study involves a relational database which was 
created by downloading the flat files from various websites. The data was parsed using 
Python. Python is general purpose, high level programming language. It has a fully 
dynamic type system and automatic memory management. It is used as a scripting 
language for web applications. Python 2.7.2 was used for the current study [56-58].  
Django:  Django is a high-level Python Web framework that helps in rapid application 
development and clean design [59]. It consists of object relational mapper to help define 
the data models entirely in Python giving a rich dynamic database API. It provides an 
automatic design interface to help add and modify contents. Django 1.3 version was used 
for the development of the application [59].  
SQLite: SQLite is a software library the source code of which is in public domain. It is the 
most widely used serverless self-contained SQL database engine [60]. It is compatible with 
most of the programming languages such as C, C++, C#, Visual Basic, Java, Python etc. 
The version of SQLite used for the application was 3.7.8. 
The system involves a relational database which was created by downloading the 
flat files from various websites and only the data needed for the study was used out of the 
  
entire flat file. The data required for the study was the drug name, the DrugID, the 
UniProtID and the information of the Proteins, the GeneID as well as the MIM# for the 
disease and the disease name. 
        
             Figure 3.1
3.6.3 Data Sources  
Most of the data used for this work was taken from DrugBank website [8,61,62] 
which is a freely available public resource. The DrugBank
cheminformatics resource. It combines the chemical, pharmacological and pharmaceutical 
information of a drug with comprehensive drug target information including protein and 
gene sequences, structure, and pathway information. There are 6707 drugs listed in 
DrugBank. The information about each drug is given in a DrugCard which contains more 
than 150 data fields with information of the drug/chemical data as well as the drug target or 
protein data. Of these fields only the Generic Name of the drug and the Accession number 
25 
Figure 3.1 shows the Omim Architecture.  
 
. The Omim Component Architecture 
 database is a bioinformatics and 
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which was used as an Identifier of the drug were used. Some of the data taken directly from 
DrugBank is presented below in Table 3.1. 
Identification 
Name Tacrine 
Accession Number DB00382 (APRD00690)  
Weight Average: 198.2637 
Chemical Formula C13H14N2 
Properties 
State solid 
Melting point 183.5 
o
C 
External Links 
Resource Link 
KEGG Compound C01453  
PubChem Compound 1935 
Drugs.com http://en.wikipedia.org/wiki/Tacrine  
Wikipedia http://en.wikipedia.org/wiki/Tacrine  
Targets 
1. Acetylcholinesterase 
Pharmacological action: yes 
Actions: inhibitor 
Rapidly hydrolyzes choline released into the synapse 
Organism class: human 
UniProt ID: P22303  
Gene: ACHE  
  
2. Cholinesterase 
Pharmacological action: yes 
Actions: inhibitor 
An acylcholine + H(2)O = choline + a carboxylate 
Organism class: human 
UniProt ID: P06276  
Gene: BCHE  
Enzymes 
1. Cytochrome P450 1A2 
Actions: substrate 
UniProt ID: P05177 
 
Table 3.1. Sample Data from DrugBank 
The information about the Protein Targets and the Enzymes was taken from 
UniProt website [51]. UniProt [63-65] is a freely accessible knowledgebase that provides 
high quality protein sequence and functional information to the scientific community 
mostly dealing with the biological data. Out of the different databases in UniProt only 
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UniProtKB [65] was used for this study. In release 2010_09 of 10 August 2010, 
UniProtKB/Swiss-Prot contained 519,348 entries [65]. Taking the above example from the 
drugbank it is evident that one of the Protein Targets is Acetylcholinesterase with UniProt 
ID as P22303 and Gene as ACHE. For the above UniProtID the data for Protein Target is 
given. The data given below in Table 3.2 is a part of data that is present in the UniProt 
website against UniProtID P22303. It is also found that this ID has the reference to Tacrine 
from DrugBank.  
P22303 (ACES_HUMAN) Reviewed, UniProtKB/Swiss-Prot 
Protein names Recommended name: 
Acetylcholinesterase 
Short name=AChE 
Gene names Name: ACHE 
Organism Homo sapiens (Human) 
Protein attributes 
Sequence length 614 AA. 
Cross-references 
Sequence databases 
EMBL 
 
M55040 mRNA. Translation: AAA68151.1. 
GenBank S71129 Genomic DNA. Translation: AAC60618.1. Sequence problems.. 
3D structure databases 
Protein-protein interaction databases 
IntAct P22303. 6 interactions. 
Genome annotation databases 
GeneID 43 
KEGG hsa:43.  
UCSC uc003uxd.1. human.  
Organism-specific databases 
CTD 43 
GeneCards GC07M095117.  
MIM 100740. gene+phenotype. 112100. phenotype.  
Other 
Drugbank DB00989. Rivastigmine. 
DB00382. Tacrine. 
Table 3.2. Sample Data from www.uniprot.org  
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GeneCards is a database of human genes that provides genomic, proteomic, 
transcriptomic, genetic and functional information on all known and predicted human 
genes [66-68]. Information that is present in GeneCards includes disease relationships, 
mutations, gene expression, gene function, pathways, protein-protein interactions, related 
drugs & compounds as well as links to other information such as antibodies, recombinant 
proteins, clones etc. GeneCards was used to find the details of the gene involved in the 
disease. The total number of GeneCards entries is 67217. Taking the same example of 
Tacrine above, the gene is given as ACHE which has the cross-reference to GeneCards 
website. Table 3.3 gives the sample data from GeneCards website 
ACHE Gene   acetylcholinesterase   
 
(Previous names: acetylcholinesterase (YT blood 
group), acetylcholinesterase (Yt blood group) )   
GC07M100487      (Previous symbol: YT)   
Aliases & 
Descriptions Aliases & Descriptions 
for ACHE gene 
acetylcholinesterase 
OTTHUMP00
000211347 
(According to 
HGNC, Entrez Gene, 
UniProtKB/Swiss-
Prot, OMIM,  
External 
Ids:     
HGNC: 
108   
Entrez Gene: 
43   
Ensembl: 
ENSG000000870857  
UniProtKB: 
P22303    
Export aliases for ACHE gene to outside databases  
 
Previous GC identifers: GC07M099022 GC07M100085 GC07M100099 
GC07M100132 GC07M100325 GC07M095117 
Summaries for 
ACHE gene Entrez Gene summary for ACHE: 
(According to Entrez 
Gene, Wikipedia's 
Gene Wiki, 
UniProtKB/  Swiss-
Prot  
physostigmine used to treat glaucoma. AChE inhibitors are also used in the 
management of mild to moderate Alzheimer's disease. 
Gene Wiki entry for ACHE (Acetylcholinesterase) 
Gene Function for 
ACHE gene 
Function Summary: 
(According to 
UniProtKB, Animal 
models from MGI 
May 11 2011,  
     UniProtKB/Swiss-Prot: ACES_HUMAN, P22303  
Function: Terminates signal transduction at the neuromuscular junction by rapid 
hydrolysis of the acetylcholine  
        Table 3.3. Sample Data from www.genecards.org 
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The drug obtained from the drugbank website was linked to the disease through a 
path. The details of the disease to which it is linked is found in OMIM. Online Mendelian 
Inheritance in Man (OMIM) is a database that consists of all the known diseases with a 
genetic component. It also links these diseases to the relevant genes in the human genome. 
All diseases may not be linked to the human genome as it is still in the developmental 
stage.  OMIM provides references for further research and tools for genomic analysis of a 
catalogued gene [12,69]. It is one of the databases that have been used by U.S. National 
Center for Biotechnology Information (NCBI). The Protein target Acetylcholinesterase was 
linked to Alzheimer’s disease as Tacrine is a drug that is used for the treatment of 
Alzheimer’s disease at nearly all stages.  
For the current study the following schema given in Figure 3.2 was used to link the 
entities from various sources: The drug name, properties, enzymes and protein targets 
obtained from DrugBank are linked with the genes to find out which genes are affected by 
the disease.  
 
 
 
 
 
Figure 3.2. Schema  
 
Drug 
Protein 
Gene 
Disease 
Name 
Id 
Name id 
UniProtID 
GeneID 
Mim# 
Name 
Name MIM# 
Description 
Symbol 
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3.6.4 Ontological Management 
Ontology of the drugs and the diseases as well as the intermediaries was developed.  
Protégé was used to develop the ontology. Ontology mapping was carried out to find the 
relation between the drugs and the diseases as following:  
1. The Drug was taken from DrugBank website [50]. The drug had a unique Identifier 
the Drugbank ID by which it is identified. The website contains all the information 
about the given drug.  
2. The drug has mechanism of action on the disease which is carried out with the help 
of target proteins and enzymes. The drug may inhibit the action of a protein.  
3. The protein targets and the enzymes have UniProtID. They are related to genes with 
the help of GeneID. Each protein target and enzyme is transcribed by a gene.  
4. Each protein target and enzyme also contains a unique MIM#. With the help of this 
MIM# it is related to the disease it affects. The information of disease is given in 
the OMIM website. However, all genes on the human genome have not been 
mapped to OMIM. Hence, the disease name was used to link to the gene and drugs. 
To study the relationship between drugs and diseases a high level ontology suitable 
for the current work was developed. The goal here was to devise a drug- and disease-
centric knowledge framework that is helpful for both data integration and knowledge 
discovery. Ontology of the drugs and the diseases as well as the intermediaries was 
developed. Only the fields that were considered for study were taken to develop the 
ontology. The other fields could be obtained from the respective website just like in a 
database management system. The required number of classes were defined for this work 
which could give the semantic relationship between the drug and the disease including the 
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biological entities that a disease may affect such as the genes. Hence 6 different classes 
with 6 properties were defined. The ontology developed here consists of different triples 
for every drug to disease relationship as given in Figure 3.3. With the vast data available on 
the Internet and with the growing nature of the data, no ontology can be complete. 
However, the work needs to be simplified so that the integration of the existing and future 
data could be simplified and the desired semantic associations could be obtained.  
    Figure 3.3. Screenshot of the Ontology from Protégé  
 Ontology mapping or integration of data sources was carried out by identifying the 
drug from DrugBank by accession number; identifying the protein that it inhibits; 
associating the drug and drug targets to the genes and subsequently with the diseases. 
The ontological organization is handled by the relational database and manages 
entities, predicates, and triples made up of those entities and predicates. All entities and 
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predicates are identified by a unique key that is taken from the different websites. This key 
is indexed in the database to provide performance for the searching. The user manages the 
ontology from the interface through individual components for entities, predicates, and 
triples so that the management happens separately from all other components.  
The drug related data compiled from DrugBank contains comprehensive 
information about Protein targets and enzymes related to drugs. The data set contains 6707 
drugs out of which 1436 are FDA approved.  The present system parsed the data of all 
drugs for the integration with other data. The protein data was also parsed and was mapped 
to the gene data from GeneCards as well as OMIM websites for mapping to different 
diseases. The application found the associations between drug and protein targets as well as 
enzymes. The number of protein targets/enzymes/transporter/carrier of the drugs in drug 
bank was found to be 4228. Each protein and enzyme is coded by a gene. The details of the 
proteins can be obtained from the UniProt database using the UniProtID. 
The Algorithm used here is Iterative Deepening Depth First Search which searches 
all its neighbors until the goal is reached. This algorithm was used to minimize space and 
time complexity for a finite graph and to provide complete and optimal complex paths. 
Complex relations can be represented as a graph with a start node and a goal node. 
Different methods can be used to find a complex relation between two entities. An 
important measure for these complex relations is the number of hops it takes to reach en 
from e1. However, since this work is limited to finite set and the number of hops are limited 
to a maximum of 4.  
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Example1: Complex relation discovery for antimalarial drugs  
The main goal of this paper is to discover complex semantic relationships between 
drugs and diseases as well as the target proteins or enzymes and the genes that are affected 
by those proteins or enzymes. If the relationship exists through intermediate entities it can 
be expressed as a chained triple. Every element in a RDF triple is a Uniform Resource 
Identifier (URI). When two resources have the same URI they are said to be identical and 
all data for identical resources is merged.   
Various antimalarial drugs that are commonly used for the treatment of malaria 
were used to carry out the study.  A list of the antimalarial drugs is compiled from the 
literature [70] and used   in study.  Some drugs have been indicated as having more than 
one use and malaria being the new indication for such drugs were also considered for 
study.  The Protein Targets, GeneID and MIM# were taken from drugbank. Thus 
Chloroquine commonly used for treatment of malaria was taken from drugbank, has the 
accession number as DB00608. The drug has four targets as Ferriprotoporphyrin IX, 
Glutathione S-transferase A2, Tumor necrosis factor, Toll-like receptor 9.  The UniProt ID 
is given gives the detailed information about the protein and the GeneID gives the detailed 
information about the gene from the GeneCards website. The relationship can be defined as 
chained triples. The Table 3.4 below shows the relationship between the drug, Chloroquine, 
and the disease, Malaria, using MIM#.  
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Subject Predicate Object 
Chloroquine(DB00608) hasProteinTarget Tumor Necrosis Factor 
Tumor Necrosis Factor hasUniProtID, 
hasAssociatedGene  
P01375,                             
TNF 
TNF hasMIM# 191160 
191160 associatedWith Malaria 
Table 3.4. Relationship between the Drug and Disease through MIM# 
However, in the example below in Table 3.5, the gene, DHFR, treats the disease by 
acting on the metabolism of the parasite, Plasmodium falciparum and Plasmodium vivax, 
known to cause malaria. Hence, this gene has been mapped to OMIM using the MIM# that 
corresponds to the metabolism rather than directly to Malaria. Since, the disease name was 
used, the application found a relationship directly with the disease 
Subject Predicate Object 
Proguanil(DB01131) hasProteinTarget Dihydrofolate reductase 
Dihydrofolate reductase hasUniProtID, 
hasAssociatedGene  
P00374,                             
DHFR 
DHFR associatedWith Malaria 
Table 3.5. Relationship between Drug and Disease without the Use of MIM# 
Some of the known antimalarial drugs contain Ferriprotoporphyrin IX. This 
compound is known to form cytotoxic complexes with the antimalarial drugs that cause 
plasmodial membrane damage. However, this compound does not have any UniProtID, 
GeneID associated with it and there is little information about this compound on drugbank. 
But this compound has been known to be used in the treatment of malaria. Table 3.6 shows 
direct relationship with the disease. 
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Subject Predicate Object 
Chloroquine (DB00608) 
Halofantrine (DB01218) 
Mefloquine (DB00358) 
Primaquine(DB01087) 
Amodiaquine (DB00613) 
Quinine (DB00468) 
hasProteinTarget Ferriprotoporphyrin IX 
Ferriprotoporphyrin IX associatedWith Malaria 
Table 3.6. Relationship between Drug and Disease Directly through Protein 
Example 2. Finding relations to demonstrate Polypharmacology of drugs 
The drugs that are already effective against one disease can also be used for the 
treatment of other diseases. Using the same drug against other diseases can be highly 
beneficial [37-39]. Some drugs have been reported from the literature [71,72] with original 
and new uses which are different than their original uses for which they had been approved. 
Thalidomide had been earlier approved as a drug for sedation, nausea and insomnia. It is 
also being used in the treatment of multiple myloma [73]. Acetylsalicylic acid, commonly 
called as Aspirin [74,75] has been used as analgesic and antipyretic to reduce aches and 
pains and fever for a long time. It is also being used in cardiology to prevent heart attacks, 
strokes and blood clotting due to its antiplatelet activity [76]. Also Miltefosine used in the 
treatment of Cancer [77] has the new indication as Visceral leishmania [78]. A very 
common example is of Sildenafil which was earlier used for hypertension [79] is now 
being used for male erectile dysfunction in the name of Viagra [80]. 
Polypharmacological properties of the drugs can be studied by finding the relation 
of drugs to proteins and genes and the diseases. The relationships may involve many 
different paths originating from one disease to a drug and vice-versa with intermediate 
genes and protein targets. If two drugs have at least two same targets, they will show the 
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polypharmacological properties. Alzheimer’s disease is generally treated by inhibiting the 
enzymes Acetylcholinesterase and Cholinesterase. The gene that codes 
Acetylcholinesterase is ACHE which is a known factor in Alzheimer’s disease and the 
gene that codes Cholinesterase is BCHE. There are a number of approved drugs in 
drugbank that are known to act as the inhibitors of Acetylcholinesterase as well as 
Cholinesterase. Of the 16 approved drugs in drugbank 4 drugs, namely, Tacrine, 
Rivastigmine, Galantamine and Choline  contained both Acetylcholinesterase as well as 
Cholinesterase and one Donepezil contained Acetylcholinesterase. Tacrine is given as an 
example in Figure 3.4. 
 
 
 
  Figure 3.4. More than 1 Path from Drug to Disease 
The experimental drugs such as Methylphosphinic Acid, 2-(N-Morpholino)-
Ethanesulfonic Acid or Fucose could be the potential novel drugs and may show the 
polypharmacological properties. Methylphosphinic Acid has both Acetylcholinesterase as 
well as Cholinesterase as the principal components. Hence, it could be used for the 
treatment of Alzheimer’s Disease whereas the other two act on as many as 30 proteins. 
They should be studied for more than one indication as they are being developed. They 
might be helpful in treating more than one disease including Alzheimer’s Disease, 
Myasthenia Gravis and Glaucoma which also involve Acetylcholinesterase. 
Tacrine 
ACHE 
BCHE BCHE 
ACHE 
Alzheimer’s Disease 
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Example 3. Finding Drug-gene-disease relationship 
Since at least one gene is involved in all the diseases, an attempt was made to find 
the relationship between drug, gene and the disease. The drug-gene-disease relationship 
was studied for the gene ACHE. Alzheimer’s disease is generally treated by inhibiting the 
enzyme Acetylcholinesterase. The gene that codes Acetylcholinesterase is ACHE which is 
a known factor in Alzheimer’s disease. There are a number of approved drugs in drugbank 
that are known to act as the inhibitors of Acetylcholinesterase. These drugs could be 
studied for their potential use for the treatment of Alzheimer’s disease. A study is carried 
out using a gene ACHE, which had been involved in a number of diseases. It was found 
that as many as 50 drugs act on ACHE some of them still being in the experimental stage. 
Only approved drugs were considered for study. Although all the drugs act as the inhibitors 
of Acetylcholinesterase there are some drugs that help in the treatment of Alzheimer’s 
disease, some for Myasthenia Gravis and some for Glaucoma (Figure 3.5).   
Glaucoma        Myasthenia Gravis 
Isoflurophate                     Demecarium    Ambenonium       Pyridostigmine      
           Physostigmine      Neostigmine             Edrophonium     
         
          Pralidoxime  
               Tubocurarine 
  
 Tacrine     Rivastigmine     Galantamine  
   Choline    Donepezil  
           
 
Alzheimer’s Disease  
                   Figure 3.5. The Drug-Disease-Gene Relationship for Gene ACHE 
ACHEE 
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Protein is a chain of polypeptides linked together. A polypeptide is a linear chain of 
amino acids linked together by means of a peptide (- H – N – CO -) bond.  Enzymes are 
proteins that catalyze a chemical reaction in the human body. A polypeptide chain in a 
protein is coded by a particular gene. A gene is made up of a genetic code. The sequence of 
a genetic code results in the sequence of amino acids in a polypeptide. In other words each 
gene codes a polypeptide which is contained in a protein. The same polypeptide may be 
contained in more than one protein. Different polypeptides contained in one protein may be 
synthesized by different genes. Hence, a many-to-many relationship exists between 
proteins and genes where as a one-to-one relationship exists between a polypeptide and a 
gene. A gene may be involved in causing a disease by synthesizing a protein/enzyme. A 
drug acts as an inhibitor for the action of a protein to cure a disease. It is assumed that if a 
gene has been proved to cause a disease and if a drug cures that disease, then if the gene is 
involved in another disease, then the same drug may find potential use in the treatment of 
that disease. This needs further study.  In the current study, three drugs namely Tacrine that 
has been used primarily for the treatment of Alzheimer’s disease, Pyridostigmine that has 
been used for the treatment of Myasthenia Gravis and Demecarium used for the treatment 
of Glaucoma were considered. As per assumption any of the above drugs could be used for 
the treatment of the other disease as well. However, this assumption needs further study. 
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CHAPTER 4. CONCLUSION AND FUTURE WORK 
4.1 Conclusion 
A large number of diseases have been known to affect humans every day. 
Computational methods have been proposed to find the disease genes, protein interaction 
etc. However, there have been few methods that have been proposed to facilitate drug 
development. Large amount of biological and chemical data is present on the Internet in 
public databases. As the Internet expands to contain more and more data, information 
definition and searching is going to become increasingly important. Soon it will be 
impossible for humans to digest all the content on the web by themselves.  
To solve the aforementioned problem, advantage of the recent Semantic Web 
technologies was taken to solve drug discovery problem. By extracting metadata of web 
resources, the current system can now perform more complex searches and discover more 
complex relationships between data that only human users could once do. An intelligent 
semantics-based searching scheme has been proposed in this paper that discovers complex 
semantic relations between the drugs and diseases.  In this proposed scheme, complex 
semantic relations, identified by the chaining of the ontological triples in the metadata will 
allow to identify links in seemingly unrelated resources or ontological structures.  The 
Iterative Deepening Depth First Search algorithm along has been used along with ranking 
and other heuristic pruning algorithms. The system described in this paper has the ability to 
parse the data from the websites and only the data necessary for the current work is used. 
This makes handling of the enormous data on the Internet easier. Real web data has been 
used to test the proposed system. 
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4.2 Future Work 
 As drug discovery is a very expensive and time-consuming process, 
polypharmacology is a better option for the treatment of the diseases. The effect of the 
existing drugs on the biological systems could be studied for their new indications and their 
potential use.  The biological and chemical data present on the Internet can be studied and 
in combination of systems biology, chemogenomics and bioinformatics the drugs with the 
new indications could be developed. The current system can be easily extended to use an 
efficient data management system in order to maintain a high performance.  
1. In the present work, the data is used directly from the websites. This work can 
extended by incorporating more websites that contain other comprehensive data 
about the diseases such as their indications, the phenotype information, the 
pathways they affect, the chemical structure of the drugs etc and finding the 
semantic relations between them. The diseases as well as drugs could be studied for 
their similarities and clustered together. The polypharmacological properties of the 
drugs affecting one disease could be studied so that another disease with the similar 
indications may have the possibility of being treated with existing drugs.  
2. The search algorithm can be updated and a more optimized search algorithm is 
needed which could include weights in the algorithm and also studies could be 
carried out in a particular context. 
3. The ranking algorithm can be implemented to find more appropriate drug for a 
particular disease. The polypharmacological property of the drug could be studied 
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in a particular context. The ranking algorithm could include the context as well as 
the other heuristics. 
All this is possible because of the web technology used and because of the component 
nature of the software- plus the planned requirements changes were included in the 
code design and architecture.   
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